In the first place, Shionogi's new coronavirus infectious disease treatment drug, which has not been shown to prevent aggravation or suppress mortality at the primary endpoint of the clinical trial, is approved only by reducing the viral load at the surrogate endpoint ...? ?? I didn't really think it was so dangerous ... it wouldn't be approved anywhere else ... frowning_face_with_open_mouth